头孢洛林治疗对小鼠盲肠内容物中产毒艰难梭菌生长和毒素产生的影响。
Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.
机构信息
Research Service, Cleveland VA Medical Center, 10701 East Blvd., Cleveland, OH 44106, USA.
出版信息
Antimicrob Agents Chemother. 2011 May;55(5):2174-7. doi: 10.1128/AAC.01612-10. Epub 2011 Feb 22.
Abstract
Ceftobiprole and ceftobiprole medocaril did not promote growth of or toxin production by Clostridium difficile in mouse cecal contents, whereas ceftazidime, cefoxitin, ceftriaxone, cefotaxime, and ertapenem did. The relatively low propensity of ceftobiprole to promote C. difficile was attributable to inhibitory activity against C. difficile and sparing of anaerobic microflora.
摘要
头孢洛林和头孢洛林酯在小鼠盲肠内容物中既不促进艰难梭菌生长也不促进其产毒，而头孢他啶、头孢西丁、头孢曲松、头孢噻肟和厄他培南则有此作用。头孢洛林相对低的促艰难梭菌生长能力归因于其对艰难梭菌的抑制活性和对厌氧微生物群落的保护作用。
相似文献
1
Effect of ceftobiprole treatment on growth of and toxin production by Clostridium difficile in cecal contents of mice.头孢洛林治疗对小鼠盲肠内容物中产毒艰难梭菌生长和毒素产生的影响。
Antimicrob Agents Chemother. 2011 May;55(5):2174-7. doi: 10.1128/AAC.01612-10. Epub 2011 Feb 22.
2
Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.替加环素对结肠中艰难梭菌具有抑制活性，并且不会促进其生长或毒素产生。
Antimicrob Agents Chemother. 2011 Feb;55(2):546-9. doi: 10.1128/AAC.00839-10. Epub 2010 Dec 6.
3
Effect of antibiotic treatment on growth of and toxin production by Clostridium difficile in the cecal contents of mice.抗生素治疗对艰难梭菌在小鼠盲肠内容物中的生长及毒素产生的影响。
Antimicrob Agents Chemother. 2005 Aug;49(8):3529-32. doi: 10.1128/AAC.49.8.3529-3532.2005.
4
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.氟喹诺酮治疗对小鼠盲肠内容物中流行和非流行艰难梭菌菌株生长及毒素产生的影响。
Antimicrob Agents Chemother. 2007 Aug;51(8):2674-8. doi: 10.1128/AAC.01582-06. Epub 2007 Jun 11.
5
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.头孢比普：一种广谱抗耐甲氧西林金黄色葡萄球菌头孢菌素的综述。
Am J Clin Dermatol. 2008;9(4):245-54. doi: 10.2165/00128071-200809040-00004.
6
Evaluation of antimicrobial activity of ceftaroline against Clostridium difficile and propensity to induce C. difficile infection in an in vitro human gut model.评估头孢洛林对艰难梭菌的抗菌活性及其在体外人类肠道模型中诱导艰难梭菌感染的倾向。
J Antimicrob Chemother. 2013 Aug;68(8):1842-9. doi: 10.1093/jac/dkt107. Epub 2013 Apr 3.
7
Kibdelomycin is a potent and selective agent against toxigenic Clostridium difficile.瑞斯托霉素是一种针对产毒素艰难梭菌的强效且具选择性的药物。
Antimicrob Agents Chemother. 2014;58(4):2387-92. doi: 10.1128/AAC.00021-14. Epub 2014 Feb 10.
8
Examination of potential mechanisms to explain the association between proton pump inhibitors and Clostridium difficile infection.探讨解释质子泵抑制剂与艰难梭菌感染之间关联的潜在机制。
Antimicrob Agents Chemother. 2009 Oct;53(10):4133-7. doi: 10.1128/AAC.00252-09. Epub 2009 Aug 10.
9
Lactic acid production by Streptococcus thermophilus alters Clostridium difficile infection and in vitro Toxin A production.嗜热链球菌产乳酸改变艰难梭菌感染和体外产毒。
Gut Microbes. 2012 Nov-Dec;3(6):523-9. doi: 10.4161/gmic.21757. Epub 2012 Aug 16.
10
Ceftobiprole Medocaril: BAL5788, JNJ 30982081, JNJ30982081, RO 65-5788, RO 655788.头孢比普甲磺酸盐：BAL5788、JNJ 30982081、JNJ30982081、RO 65-5788、RO 655788。
Drugs R D. 2006;7(5):305-11. doi: 10.2165/00126839-200607050-00003.
引用本文的文献
1
Issues beyond resistance: inadequate antibiotic therapy and bacterial hypervirulence.耐药性之外的问题：抗生素治疗不足与细菌超毒力
FEMS Microbes. 2020 Oct 17;1(1):xtaa004. doi: 10.1093/femsmc/xtaa004. eCollection 2020 Sep.
2
Concurrent and Subsequent Co-Infections of Colitis in the Era of Gut Microbiota and Expanding Treatment Options.肠道微生物群时代及治疗选择不断扩展背景下结肠炎的并发和后续合并感染
Microorganisms. 2022 Jun 23;10(7):1275. doi: 10.3390/microorganisms10071275.
3
Safety and tolerability of ceftobiprole.头孢比普的安全性与耐受性。
Rev Esp Quimioter. 2019 Sep;32 Suppl 3(Suppl 3):34-36.
4
Activity of Tedizolid, Dalbavancin, and Ceftobiprole Against .替加环素、达巴万星和头孢洛林对……的活性
Front Microbiol. 2018 Jun 11;9:1256. doi: 10.3389/fmicb.2018.01256. eCollection 2018.
5
Role of cephalosporins in the era of Clostridium difficile infection.艰难梭菌感染时代头孢菌素的作用
J Antimicrob Chemother. 2017 Jan;72(1):1-18. doi: 10.1093/jac/dkw385. Epub 2016 Sep 22.
6
Pharmacokinetics and Dosing of Ceftobiprole Medocaril for the Treatment of Hospital- and Community-Acquired Pneumonia in Different Patient Populations.头孢托罗培南治疗不同患者群体医院获得性肺炎和社区获得性肺炎的药代动力学及给药剂量
Clin Pharmacokinet. 2016 Dec;55(12):1507-1520. doi: 10.1007/s40262-016-0418-z.
7
Antimicrobial Resistance and Reduced Susceptibility in Clostridium difficile: Potential Consequences for Induction, Treatment, and Recurrence of C. difficile Infection.艰难梭菌的抗药性和耐药性降低：对艰难梭菌感染的诱导、治疗和复发的潜在影响。
Antibiotics (Basel). 2015 Jul 10;4(3):267-98. doi: 10.3390/antibiotics4030267.
8
Ceftobiprole for the treatment of pneumonia: a European perspective.头孢比普用于治疗肺炎：欧洲视角
Drug Des Devel Ther. 2015 Aug 18;9:4565-72. doi: 10.2147/DDDT.S56616. eCollection 2015.
9
Association of tcdA+/tcdB+ Clostridium difficile Genotype with Emergence of Multidrug-Resistant Strains Conferring Metronidazole Resistant Phenotype.tcdA+/tcdB+艰难梭菌基因型与赋予甲硝唑耐药表型的多重耐药菌株出现的关联。
Iran Biomed J. 2015;19(3):143-8. doi: 10.7508/ibj.2015.03.003. Epub 2015 Jun 6.
10
Subinhibitory antibiotic therapy alters recurrent urinary tract infection pathogenesis through modulation of bacterial virulence and host immunity.亚抑菌剂量抗生素治疗通过调节细菌毒力和宿主免疫力改变复发性尿路感染的发病机制。
mBio. 2015 Mar 31;6(2):e00356-15. doi: 10.1128/mBio.00356-15.
本文引用的文献
1
Tigecycline exhibits inhibitory activity against Clostridium difficile in the colon of mice and does not promote growth or toxin production.替加环素对结肠中艰难梭菌具有抑制活性，并且不会促进其生长或毒素产生。
Antimicrob Agents Chemother. 2011 Feb;55(2):546-9. doi: 10.1128/AAC.00839-10. Epub 2010 Dec 6.
2
Effect of ceftobiprole on the normal human intestinal microflora.头孢托罗对正常人体肠道菌群的影响。
Int J Antimicrob Agents. 2010 Dec;36(6):537-41. doi: 10.1016/j.ijantimicag.2010.07.021.
3
Does my patient have Clostridium difficile infection?我的患者是否患有艰难梭菌感染？
Ann Intern Med. 2009 Aug 4;151(3):176-9. doi: 10.7326/0003-4819-151-3-200908040-00005.
4
Effective and reduced-cost modified selective medium for isolation of Clostridium difficile.用于艰难梭菌分离的高效低成本改良选择性培养基
J Clin Microbiol. 2009 Feb;47(2):397-400. doi: 10.1128/JCM.01591-08. Epub 2008 Dec 10.
5
Antimicrobial-associated risk factors for Clostridium difficile infection.艰难梭菌感染的抗菌药物相关危险因素。
Clin Infect Dis. 2008 Jan 15;46 Suppl 1:S19-31. doi: 10.1086/521859.
6
Pharmacokinetics and pharmacodynamics of ceftobiprole, an anti-MRSA cephalosporin with broad-spectrum activity.头孢比普的药代动力学和药效学，一种具有广谱活性的抗耐甲氧西林金黄色葡萄球菌头孢菌素。
Clin Pharmacokinet. 2008;47(1):21-33. doi: 10.2165/00003088-200847010-00003.
7
Effect of fluoroquinolone treatment on growth of and toxin production by epidemic and nonepidemic clostridium difficile strains in the cecal contents of mice.氟喹诺酮治疗对小鼠盲肠内容物中流行和非流行艰难梭菌菌株生长及毒素产生的影响。
Antimicrob Agents Chemother. 2007 Aug;51(8):2674-8. doi: 10.1128/AAC.01582-06. Epub 2007 Jun 11.
8
Antianaerobe activity of ceftobiprole, a new broad-spectrum cephalosporin.
Diagn Microbiol Infect Dis. 2007 May;58(1):133-6. doi: 10.1016/j.diagmicrobio.2006.10.015. Epub 2007 Jan 19.
9
Effect of carbapenem administration on establishment of intestinal colonization by vancomycin-resistant enterococci and Klebsiella pneumoniae in mice.碳青霉烯类药物给药对小鼠体内耐万古霉素肠球菌和肺炎克雷伯菌肠道定植的影响。
Antimicrob Agents Chemother. 2007 Jan;51(1):372-5. doi: 10.1128/AAC.00355-06. Epub 2006 Oct 16.
10
In vitro activity of ceftobiprole against aerobic and anaerobic strains isolated from diabetic foot infections.头孢比普对从糖尿病足感染中分离出的需氧菌和厌氧菌的体外活性。
Antimicrob Agents Chemother. 2006 Nov;50(11):3959-62. doi: 10.1128/AAC.00722-06. Epub 2006 Sep 18.
Zotero 插件